Alzheimer's disease is the most common cause of dementia. This is an irreversible progressive brain disease that slowly destroys brain cells, memory and the thought of destroying and finally, the ability to perform simple tasks. The incidence of Alzheimer's disease is increasing, however, beyond simply treating symptoms, treatment of the underlying causes are beginning to be addressed by researchers. Discover the latest information on the causes, treatments prevalence, current and new treatment strategies that lie ahead.

What causes Alzheimer's disease?

Regardless of how the disease starts, still unknown, it is known that brain damage begins as soon as 10 to 20 years before the problems are obvious. This occurs in the formation of abnormal clumps (amyloid plaques) and tangled bundles of fibers (neurofibrillary tangles). As the plaques and tangles form, healthy neurons lose their ability to function and eventually die. This process extends the damage to the hippocampus, a structure of proximity that is essential for memory formation. Since the death of increases neurons, the brain regions affected begins to decrease. In the last stage of Alzheimer's disease, the damage is widespread and brain tissue decreased significant.

It is likely that over a long period of time, changes related to age, genetics, environmental and lifestyle occur and contribute to the progression of the disease.

1. Related by age include brain atrophy (shrinkage) of parts of the brain, inflammation and the production of unstable molecules called free radicals that prevent neurons.

2 -. Genetics People who develop Alzheimer's disease before age 65 have generally a transfer or a permanent change in one of three genes located on chromosomes inherited 1 (Sen2) 14 (SEN1) and 21 (APA, A4). These mutations cause "early" disease, however, not all first cases are caused by these mutations. Most people have "late" disease that usually develops after age 65, and is related to the APOE gene. With APOE ε4 ApoE way, increases the risk of someone getting Alzheimer's disease. Forty percent of all people who develop late-onset Alzheimer's APOE ε4 effect. However, the achievement of APOE ε4 does not always mean a person will develop Alzheimer's disease, and people do not carry APOE ε4 ways you can still develop the disease.

additional genes may influence the development of late-onset disease. Scientists have identified variants of SORL1, CLU, PICALM and CR1 genes may play a role in the risk of late-onset Alzheimer's disease.

3. Lifestyle news, research suggests that factors a nutritious diet, physical activity, social engagement and mental stimulating activities can help reduce the risk of cognitive decline and Alzheimer's disease. Scientists studying the associations between cognitive impairment and vascular and metabolic disorders such as heart disease, stroke, hypertension, diabetes and obesity to determine whether the reduction of risk factors for these diseases may help Alzheimer's disease.

New information Alzheimer's Disease from 2010

As indicated by the relationship between Alzheimer's Association, 2010, the new information on various aspects of the disease is obvious:

1. Prevalence

• 5.3 million Americans have Alzheimer's disease and 5.1 of them are older than 65.That is 1 to 8 persons over 65 years.
• More women suffer from the disease than men, mainly because women live longer than men.
• Less education is associated with an increased risk of developing dementia, probably due to lower cognitive reserve, a socio-economic status and less medical attention.
• Afro-Americans are twice and Hispanics and a half times likely than whites to have dementia. It is perhaps related to the incidence of hypertension, diabetes, low socioeconomic status and education.

2 The current treatment. - The U.S. Food and Drug Administration (FDA) approved

five medications to treat the symptoms of Alzheimer's Disease stage.Â

• Donepezil (Aricept) for all stages.Â
• Galatamine (Reminyl), rivastigmine (Exelon) and tacrine (Cognex) for mild to moderate stages.Â
• Memantine (Namenda) moderately severe stages.

3. Future treatments and three different clinical trials begin to determine the future

diagnosis and treatment of Alzheimer's disease

• A better diagnosis-use of biomarkers to identify the disease at an early stage, when symptoms and disorders are milder.
• Immunoglobulin treatment with intravenous immunoglobulin IVIG to reduce the presence of amyloid plaques.Â
• eatment T Ceregene with CERE-110 - a gene therapy product designed to provide nerve growth factor (NGF) in the brain a strategy overall treatment

Audrey Robinson is a research scientist in Cell and Molecular Biology. She is dedicated to the field of cancer research and has striven to support this research through her internet business marketing products for financial education and wealth management. She is also a coach for internet marketers. Visit her website http://www.successinmasteringwealth.com/?t=ezine that offers help for those seeking financial freedom and independence as well as wealth management education.